TapImmune, Inc. (TPIV.OB) Signs License Agreement with Crucell (CRXL)
TapImmune Inc., best known for developing immunotherapeutic vaccines for cancer and infectious diseases, announced recently that it has signed a license agreement with Crucell N.V. (NASDAQ: CRXL), a global biopharmaceutical company based in the Netherlands. The license allows TapImmune to use Crucell’s proprietary PER.C6® cells in its development programs. The cell line is ideal for the development and large-scale production of a wide variety of biopharmaceuticals. Specifically, PER.C6 cells do not generate replication competent adenoviruses in the use of recombinant vaccines using adenoviral vectors, making it excellent for the production of adenoviral vectors for clinical applications. Generally, the PER.C6 cell…